{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:58:40Z","timestamp":1787497120350,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Local inflammation in axial spondyloarthritis (axSpA) leads to the release of collagen metabolites from the disease-affected tissue. We investigated whether collagen metabolites were associated with disease activity and could distinguish non-radiographic(nr)-axSpA from ankylosing spondylitis (AS). A total of 193 axSpA patients (nr-axSpA, n\u2009=\u2009121 and AS, n\u2009=\u200972) and asymptomatic controls (n\u2009=\u2009100) were included. Serum levels of metalloproteinase (MMP)-degraded collagen type I (C1M), type II (C2M), type III (C3M) and type IV (C4M2) were quantified by enzyme-linked immunosorbent assay (ELISA). All metabolites were higher in axSpA than in controls (all p\u2009&lt;\u20090.001). Serum levels of C1M, C3M, and C4M2 were increased in AS compared to nr-axSpA (43.4\u2009ng\/mL vs. 34.6; p\u2009&lt;\u20090.001, 15.4 vs. 12.8; p\u2009=\u20090.001, and 27.8 vs. 22.4; p\u2009&lt;\u20090.001). The best metabolite to differentiate between axSpA and controls was C3M (AUC 0.95; specificity 92.0, sensitivity 83.4). C1M correlated with ASDAS-CRP in nr-axSpA (\u03c1\u2009=\u20090.37; p\u2009&lt;\u20090.001) and AS (\u03c1\u2009=\u20090.57; p\u2009&lt;\u20090.001). C1M, C3M, and C4M2 were associated with ASDAS-CRP in AS and nr-axSpA after adjustment for age, gender, and disease duration. Serum levels of collagen metabolites were significantly higher in AS and nr-axSpA than in controls. Moreover, the present study indicates that collagen metabolites reflect disease activity and are useful biomarkers of axSpA.<\/jats:p>","DOI":"10.1038\/s41598-019-47502-z","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T07:19:54Z","timestamp":1564730394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis"],"prefix":"10.1038","volume":"9","author":[{"given":"Mark\u00e9ta","family":"Hu\u0161\u00e1kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160\u00e1rka","family":"Forejtov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Zegzulkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tom\u010d\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gregov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Bubov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ho\u0159\u00ednkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindra","family":"Gatterov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-8422","authenticated-orcid":false,"given":"Anne Sofie","family":"Siebuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"47502_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper, J. & Poddubnyy, D. Axial spondyloarthritis. Lancet 390, 73\u201384 (2017).","journal-title":"Lancet"},{"key":"47502_CR2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.097774","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper, J. et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68, ii1\u2013ii44 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheumatol. 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheumatol."},{"key":"47502_CR4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-017-1342-9","volume":"19","author":"WP Maksymowych","year":"2017","unstructured":"Maksymowych, W. P. et al. MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation. Arthritis Res. Ther. 19, 126 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"47502_CR5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter, J. J., van Mens, L. J., van der Heijde, D., Landewe, R. & Baeten, D. L. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res. Ther. 18, 196 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"47502_CR6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978\u2013991 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","volume":"68","author":"M Dougados","year":"2016","unstructured":"Dougados, M. et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheumatol. 68, 1904\u20131913 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"47502_CR8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy, D. et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70, 1369\u20131374 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.39542","volume":"68","author":"R Wang","year":"2016","unstructured":"Wang, R., Gabriel, S. E. & Ward, M. M. Progression of nonradiographic axial spondyloarthritis to ankylosing spondylitis: a population-based cohort study. Arthritis Rheumatol. 68, 1415\u20131421 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"47502_CR10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2016.06.005","volume":"15","author":"JM Anaya","year":"2016","unstructured":"Anaya, J. M. et al. Personalized medicine. Closing the gap between knowledge and clinical practice. Autoimmun. Rev. 15, 833\u2013842 (2016).","journal-title":"Autoimmun. Rev."},{"key":"47502_CR11","doi-asserted-by":"crossref","first-page":"vi18","DOI":"10.1093\/rheumatology\/key176","volume":"57","author":"H Marzo-Ortega","year":"2018","unstructured":"Marzo-Ortega, H., Gaffney, K. M. & Gaffney, K. Defining the target: clinical aims in axial spondyloarthritis. Rheumatology 57, vi18\u2013vi22 (2018).","journal-title":"Rheumatology"},{"key":"47502_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fimmu.2019.00305","volume":"10","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych, W. P. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front. Immunol. 10, 305 (2019).","journal-title":"Front. Immunol."},{"key":"47502_CR13","doi-asserted-by":"crossref","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos, X. & Braun, J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open 1, e000053 (2015).","journal-title":"RMD Open"},{"key":"47502_CR14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/1354750X.2015.1105497","volume":"20","author":"C Kjelgaard-Petersen","year":"2015","unstructured":"Kjelgaard-Petersen, C. et al. Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers 20, 547\u2013556 (2015).","journal-title":"Biomarkers"},{"key":"47502_CR15","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar3857","volume":"14","author":"DL Mattey","year":"2012","unstructured":"Mattey, D. L. et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res. Ther. 14, R127 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"47502_CR16","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/art.22589","volume":"56","author":"WP Maksymowych","year":"2007","unstructured":"Maksymowych, W. P. et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 56, 1846\u20131853 (2007).","journal-title":"Arthritis Rheum."},{"key":"47502_CR17","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00296-011-2237-8","volume":"32","author":"AC Bay-Jensen","year":"2012","unstructured":"Bay-Jensen, A. C. et al. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol. Int. 32, 3565\u20133572 (2012).","journal-title":"Rheumatol. Int."},{"key":"47502_CR18","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/ar4266","volume":"15","author":"AS Siebuhr","year":"2013","unstructured":"Siebuhr, A. S. et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 15, R86 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"47502_CR19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/1354750X.2011.620628","volume":"16","author":"D Leeming","year":"2011","unstructured":"Leeming, D. et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16, 616\u2013628 (2011).","journal-title":"Biomarkers"},{"key":"47502_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clinbiochem.2011.01.001","volume":"44","author":"AC Bay-Jensen","year":"2011","unstructured":"Bay-Jensen, A. C. et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM\u2013increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 44, 423\u2013429 (2011).","journal-title":"Clin. Biochem."},{"key":"47502_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/bmm.15.119","volume":"10","author":"AS Siebuhr","year":"2016","unstructured":"Siebuhr, A. S., Bay-Jensen, A. C., Karsdal, M. A., Lories, R. J. & de Vlam, K. CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis. Biomark. Med. 10, 197\u2013208 (2016).","journal-title":"Biomark. Med."},{"key":"47502_CR22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4137\/BMI.S6347","volume":"6","author":"E Vassiliadis","year":"2011","unstructured":"Vassiliadis, E. et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type III, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark. Insights 6, 49\u201358 (2011).","journal-title":"Biomark. Insights"},{"key":"47502_CR23","doi-asserted-by":"crossref","first-page":"e84934","DOI":"10.1371\/journal.pone.0084934","volume":"8","author":"JM Sand","year":"2013","unstructured":"Sand, J. M. et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis\u2013validation of two novel biomarker assays. PLoS One 8, e84934 (2013).","journal-title":"PLoS One"},{"key":"47502_CR24","doi-asserted-by":"crossref","first-page":"e54504","DOI":"10.1371\/journal.pone.0054504","volume":"8","author":"AC Bay-Jensen","year":"2013","unstructured":"Bay-Jensen, A. C. et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 8, e54504 (2013).","journal-title":"PLoS One"},{"key":"47502_CR25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 60, 717\u2013727 (2009).","journal-title":"Arthritis Rheum."},{"key":"47502_CR26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/annrheumdis-2012-201545","volume":"72","author":"CE Althoff","year":"2013","unstructured":"Althoff, C. E. et al. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann. Rheum. Dis. 72, 967\u2013973 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR27","doi-asserted-by":"crossref","first-page":"e000802","DOI":"10.1136\/rmdopen-2018-000802","volume":"5","author":"JJ de Winter","year":"2019","unstructured":"de Winter, J. J., Paramarta, J. E., de Jong, H. M., van de Sande, M. G. & Baeten, D. L. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open 5, e000802 (2019).","journal-title":"RMD Open"},{"key":"47502_CR28","volume":"15","author":"S Sun","year":"2014","unstructured":"Sun, S. et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet. Disord. 15, 93 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"47502_CR29","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.4238\/2015.June.18.28","volume":"14","author":"KG Liu","year":"2015","unstructured":"Liu, K. G., He, Q. H., Tan, J. W. & Liao, G. J. Expression of TNF-alpha, VEGF, and MMP-3 mRNAs in synovial tissues and their roles in fibroblast-mediated osteogenesis in ankylosing spondylitis. Genet. Mol. Res. 14, 6852\u20136858 (2015).","journal-title":"Genet. Mol. Res."},{"key":"47502_CR30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2011-200508","volume":"71","author":"U Kiltz","year":"2012","unstructured":"Kiltz, U. et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann. Rheum. Dis. 71, 1207\u20131211 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR31","doi-asserted-by":"crossref","first-page":"e000482","DOI":"10.1136\/rmdopen-2017-000482","volume":"3","author":"A Ruyssen-Witrand","year":"2017","unstructured":"Ruyssen-Witrand, A. et al. Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD Open 3, e000482 (2017).","journal-title":"RMD Open"},{"key":"47502_CR32","doi-asserted-by":"crossref","first-page":"e000648","DOI":"10.1136\/rmdopen-2018-000648","volume":"4","author":"AS Siebuhr","year":"2018","unstructured":"Siebuhr, A. S. et al. Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix? RMD Open 4, e000648 (2018).","journal-title":"RMD Open"},{"key":"47502_CR33","first-page":"653","volume":"35","author":"NS Gudmann","year":"2017","unstructured":"Gudmann, N. S. et al. Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity. Clin. Exp. Rheumatol. 35, 653\u2013659 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"47502_CR34","first-page":"415","volume":"35","author":"KY Kang","year":"2017","unstructured":"Kang, K. Y., Jung, J. Y., Hong, Y. S., Ju, J. H. & Park, S. H. Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis. Clin. Exp. Rheumatol. 35, 415\u2013422 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"47502_CR35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques, P. et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437\u2013445 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","volume":"30","author":"R Wang","year":"2018","unstructured":"Wang, R. & Ward, M. M. Epidemiology of axial spondyloarthritis: an update. Curr. Opin. Rheumatol. 30, 137\u2013143 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"47502_CR37","first-page":"159","volume":"34","author":"J Rueda-Gotor","year":"2016","unstructured":"Rueda-Gotor, J. et al. Subclinical atherosclerosis is not increased in patients with non-radiographic axial spondyloarthritis. Clin. Exp. Rheumatol. 34, 159\u2013160 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"47502_CR38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ebiom.2015.04.017","volume":"2","author":"K Dragsbaek","year":"2015","unstructured":"Dragsbaek, K. et al. Matrix metalloproteinase mediated type I collagen degradation - an independent risk factor for mortality in women. EBioMedicine 2, 723\u2013729 (2015).","journal-title":"EBioMedicine"},{"key":"47502_CR39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon, N. N., Paterson, J. M., Li, P., Inman, R. D. & Haroon, N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann. Intern. Med. 163, 409\u2013416 (2015).","journal-title":"Ann. Intern. Med."},{"key":"47502_CR40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/03009742.2013.863969","volume":"43","author":"LM Sun","year":"2014","unstructured":"Sun, L. M. et al. Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Scand. J. Rheumatol. 43, 301\u2013306 (2014).","journal-title":"Scand. J. Rheumatol."},{"key":"47502_CR41","unstructured":"Siebuhr, A. S. et al. Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clin. Exp. Rheumatol. Feb 11 Epub ahead of print (2019)."},{"key":"47502_CR42","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde, D. et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 1811\u20131818 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR43","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin, A. et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol. 21, 2281\u20132285 (1994).","journal-title":"J. Rheumatol."},{"key":"47502_CR44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward, L. C. et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann. Rheum. Dis. 62, 20\u201326 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"47502_CR45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin, R. & de Charro, F. EQ-5D: a measure of health status from the EuroQol group. Ann. Med. 33, 337\u2013343 (2001).","journal-title":"Ann. Med."},{"key":"47502_CR46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych, W. P. et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 53, 703\u2013709 (2005).","journal-title":"Arthritis Rheum."},{"key":"47502_CR47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00117-003-0992-6","volume":"44","author":"KG Hermann","year":"2004","unstructured":"Hermann, K. G., Braun, J., Fischer, T., Reisshauer, H. & Bollow, M. Magnetic resonance tomography of sacroiliitis: anatomy, histological pathology, MR-morphology, and grading. Radiologe 44, 217\u2013228 (2004).","journal-title":"Radiologe"},{"key":"47502_CR48","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.20446","volume":"50","author":"AJ Wanders","year":"2004","unstructured":"Wanders, A. J. et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum. 50, 2622\u20132632 (2004).","journal-title":"Arthritis Rheum."},{"key":"47502_CR49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.clinbiochem.2011.04.004","volume":"44","author":"N Barascuk","year":"2011","unstructured":"Barascuk, N. et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen\u2013A novel biomarker of atherosclerotic plaque remodeling. Clin. Biochem. 44, 900\u2013906 (2011).","journal-title":"Clin. Biochem."},{"key":"47502_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1755-1536-4-22","volume":"4","author":"SS Veidal","year":"2011","unstructured":"Veidal, S. S. et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4, 22 (2011).","journal-title":"Fibrogenesis Tissue Repair"}],"updated-by":[{"DOI":"10.1038\/s41598-020-71093-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47502-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:17:56Z","timestamp":1671261476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47502-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["47502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-47502-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"23 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.S. and A.C.B.J. are full-time employees of Nordic Bioscience, which is a privately-owned SME that develops biomarkers of fibrosis. A.C.B.J. is also a stockholder of Nordic Bioscience. The authors have no other relevant affiliation or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those previously disclosed. No writing assistance was used in the production of this manuscript. All authors of the Institute of Rheumatology (M.H., S.F., K.Z., M.T., M.G., K.B., J.H., J.G. and K.P.) declare no competing interest in this study. All authors declare no non-financial conflicts regarding to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11218"}}